Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| VRTX | CLUSTER | neutral | 2/10 | Three Vertex EVPs sold a total of $1.49M in stock over a one-week period ending July 2, 2026, representing less than 0.0 | Jul 8, 2026 |
| QURE | CLUSTER | bearish | 5/10 | Three insiders at uniQure (QURE), including the CEO and Chief Medical Officer, sold a combined $1.67M in stock within a | Jul 8, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | Four CYTK insiders (CEO, CFO, CCO, EVP R&D) sold a total of $2.32M in shares over a one-week window, but this represents | Jul 8, 2026 |
| KYMR | CLUSTER | bearish | 5/10 | CEO Nello Mainolfi sold $5.95M of KYMR stock at ~$119/share on July 7, 2026, following derivative exercises. CFO Bruce J | Jul 7, 2026 |
| ATAI | 144 | neutral | 3/10 | Director Robert Hershberg filed a Form 144 notice of intent to sell 100,000 shares of AtaiBeckley Inc. common stock, val | Jul 7, 2026 |
| SPRY | 8-K | neutral | 3/10 | ARS Pharmaceuticals announced the termination without cause of CEO Richard Lowenthal, effective immediately, and appoint | Jul 7, 2026 |
| IMNM | CLUSTER | neutral | 4/10 | Two insiders at Immunome, Director Barchas and CMO Lechleider, collectively sold ~$6.0M of stock over the past week, wit | Jul 7, 2026 |
| SUPN | COURT-RULING | bullish | 5/10 | Supernus Pharmaceuticals won a procedural ruling in its Hatch-Waxman patent infringement action against multiple generic | Jul 7, 2026 |
| ADPT | CLUSTER | bearish | 6/10 | Five insiders at Adaptive Biotechnologies, including the Chief Scientific Officer and two Chief Commercial Officers, sol | Jul 7, 2026 |
| STTK | CLUSTER | neutral | 3/10 | Two STTK insiders (Chief Medical Officer and Chief Technical Officer) sold a combined $213K in open-market sales over a | Jul 7, 2026 |
| IMNM | CLUSTER | neutral | 2/10 | Two insiders at Immunome (CMO and a director) sold shares totaling $2.19M in open-market transactions over a 7-day windo | Jul 7, 2026 |
| AZN | COURT-RULING | bearish | 5/10 | The Fifth Circuit affirmed Louisiana's Act 358, which prohibits drug manufacturers from restricting 340B discounted drug | Jul 7, 2026 |
| GLUE | CLUSTER | neutral | 2/10 | Multiple insiders at Monte Rosa Therapeutics (GLUE) sold shares totaling ~$494K over a one-week window, but the aggregat | Jul 7, 2026 |
| SION | CLUSTER | bearish | 5/10 | Three Sionna Therapeutics insiders sold a combined $10.99M in shares over a 7-day window, including two directors who ea | Jul 7, 2026 |
| TOI | 8-K | bullish | 7/10 | TOI refinanced its $86 million Deerfield convertible note by entering into a $75 million term loan with OrbiMed (maturit | Jul 7, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine announced successful formulation feasibility study for intranasal delivery of its lead candidate MEAI | Jul 7, 2026 |
| VERA | 8-K | bullish | 7/10 | Vera Therapeutics announced FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with | Jul 7, 2026 |
| REGN | ANALYST-UPGRADE | mixed | 2/10 | Benchmark double-upgraded REGN from Hold to Buy on July 7, 2026, but set a price target of $185, implying a 71.5% downsi | Jul 7, 2026 |
| VRTX | 8-K | bullish | 7/10 | Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cas | Jul 7, 2026 |
| ATHE | 6-K | bullish | 7/10 | Alterity Therapeutics received official FDA End-of-Phase 2 meeting minutes confirming the registrational pathway for ATH | Jul 7, 2026 |
| TVRD | 8-K | bullish | 7/10 | Tvardi Therapeutics disclosed Phase 1 results for its next-generation STAT3 inhibitor, TTI-109, a phosphate prodrug of T | Jul 7, 2026 |
| VXRT | 8-K | neutral | 4/10 | Vaxart reported topline 12-month safety data from the 400-participant sentinel safety cohort of its Phase 2b oral pill C | Jul 7, 2026 |
| ASRT | 25-NSE | neutral | 5/10 | Nasdaq filed a Form 25-NSE to remove Assertio Holdings' common stock from listing and SEC registration, effective July 7 | Jul 7, 2026 |
| SMNR | 8-K | neutral | 5/10 | Semnur Pharmaceuticals signed a binding term sheet with iHolding Group LLP for a $100M investment at $10/share, issuing | Jul 7, 2026 |
| ENLV | 6-K | neutral | 3/10 | Enlivex announced a 1-for-15 reverse stock split effective July 9, 2026, reducing outstanding shares from 252,480,222 to | Jul 7, 2026 |
| TTRX | 8-K | bullish | 7/10 | Turn Therapeutics announced the completion of a comprehensive interim analysis of its adaptive Phase 2 trial for GX-03 i | Jul 7, 2026 |
| SABS | 8-K | bullish | 4/10 | SAB Biotherapeutics announced that Breakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 i | Jul 7, 2026 |
| TOVX | 8-K | bullish | 5/10 | Theriva Biologics received regulatory authorization from the Spanish AEMPS to initiate the VIRAGE2 Phase 2a clinical tri | Jul 7, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP General Counsel Paul Mahon sold a combined ~$8.5M in open-market shares over a 7-day windo | Jul 7, 2026 |
| PRPH | 10-Q/A | bearish | 8/10 | ProPhase Labs filed Amendment No. 1 to its Q1 2026 10-Q solely to update the auditor review status, confirming the indep | Jul 7, 2026 |